Eli Lilly will build its first pharmaceutical plant in Germany – Kommersant

Pharmaceutical company Eli Lilly will build its first plant in Germany, in the city of Alzey (Rhineland-Palatinate). The cost of the project is estimated at €2.3 billion, and its need is due to growing demand for Eli Lilly products, in particular for drugs for obesity and diabetes.

It is planned that the new plant will begin operating in 2027. Thus, Eli Lilly will have six pharmaceutical plants in Europe. The company notes that locating the plant in Germany “will guarantee rapid access to new treatment options and reduce dependence on unstable supply chains.” The company does not indicate which drugs will be produced at the future plant in Germany.

However, the agency Reuters Citing informed sources, it reports that these drugs will include tirzepatide (trade name Mounjaro), which has approved indications for the treatment of diabetes. It has also shown effectiveness in solving the problem of obesity, although these indications are not stated in the instructions.

At the same time, last week in the United States, regulators approved the use of tirzepatide (trade name Zepbound) specifically for the treatment of obesity. In general, experts assess the global market for drugs to control excess weight as very promising, given the current demand. According to experts cited by Reuters, by the end of the decade, annual sales of such drugs will reach $100 billion.

Alena Miklashevskaya